Skip to main content Accessibility help
×
Home
Hostname: page-component-99c86f546-md8df Total loading time: 0.352 Render date: 2021-11-28T15:55:36.044Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Pharmacological management of comorbid obsessive–compulsive disorder and chronic non-affective psychosis

Published online by Cambridge University Press:  17 August 2020

Itoro Udo*
Affiliation:
Consultant psychiatrist with the Oxford Assertive Community Treatment Team, St Joseph's Healthcare, London, Ontario, and an Assistant Professor in the Division of General Psychiatry at Western University, Ontario, Canada.
Carol McDaniel
Affiliation:
Consultant psychiatrist at the Parkwood Institute, St Joseph's Healthcare, London, Ontario, and an Assistant Professor in the Division of General Psychiatry at Western University, London, Ontario, Canada.
Chidi Chima
Affiliation:
Consultant psychiatrist in the Mental Health Clinic – Alberta Health Services, Edmonton, Alberta, Canada.
*
Correspondence Itoro Udo. Email: Itoro.Udo@sjhc.london.on.ca

Summary

The comorbidity of obsessive–compulsive symptoms (OCS) in the context of schizophrenia is often not recognised by clinicians, and patients may not report these symptoms until they become severe. However, there is a reported prevalence of 10–24% for obsessive–compulsive disorder (OCD) in schizophrenia and related disorders. The onset of OCS/OCD has been noted to occur both before and after the diagnosis of schizophrenia or schizoaffective disorder. It has also been known to occur following commencement of treatment with antipsychotic medications, especially clozapine. Current literature provides limited guidance for treatment. Review of the current evidence supports: addition of selective serotonin reuptake inhibitors (SSRIs) to antipsychotics; addition of aripiprazole, amisulpride or lamotrigine; or reduction in the dosage of clozapine. There is also evidence supporting the addition of cognitive–behavioural therapy and electroconvulsive therapy (ECT). The SSRIs that are evidenced to be useful are fluvoxamine, escitalopram, sertraline and paroxetine. More studies are needed to expand the evidence base. Early targeted interventions are recommended.

Type
Article
Copyright
Copyright © The Authors 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (5th edn) (DSM-5). American Psychiatric Publishing.Google Scholar
Barnes, TRE, Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 25: 567620.CrossRefGoogle ScholarPubMed
Beduin, A, Swets, M, Machielsen, M, et al. (2012) Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. Journal of Clinical Psychiatry, 73: 1395–402.CrossRefGoogle Scholar
Bejerot, S, Edman, G, Anckarsäter, H, et al. (2014) The Brief Obsessive-Compulsive Scale (BOCS): a self-report scale for OCD and obsessive-compulsive related disorders. Nordic Journal of Psychiatry, 68: 549–59.CrossRefGoogle ScholarPubMed
Berman, I, Merson, A, Viegner, B (1998) Obsessive and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study. Journal of Nervous and Mental Diseases, 186: 150–6.CrossRefGoogle ScholarPubMed
Bottas, A, Cooke, RG, Richter, MA (2005) Comorbidity and pathophysiology of obsessive–compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia? Journal of Psychiatry and Neuroscience, 30: 187–93.Google ScholarPubMed
Cai, J, Zhang, W, Yi, Z, et al. (2013) Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology, 230: 4955.CrossRefGoogle ScholarPubMed
Coskun, M, Zoroglu, S (2009) Clozapine induced obsessions treated with sertraline in an adolescent with schizophrenia. Klinik Psikofarmakoloji Bulteni, 19: 155–8.Google Scholar
Cunill, R, Huerta-Ramos, E, Castells, X (2013) The effect of obsessive-compulsive symptomatology on executive functions in schizophrenia: a systematic review and meta-analysis. Psychiatry Research, 210: 21–8.CrossRefGoogle ScholarPubMed
Demjaha, A, Egerton, A, Murray, RM, et al. (2014) Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biological Psychiatry, 75: e11–3.CrossRefGoogle ScholarPubMed
Devi, S, Rao, NP, Badamatha, S, et al. (2015) Prevalence and clinical correlates of obsessive–compulsive disorder in schizophrenia. Comprehensive Psychiatry, 56: 141–8.CrossRefGoogle Scholar
Doyle, M, Chorcorain, AN, Griffith, E, et al. (2014) Obsessive–compulsive symptoms in patients with schizophrenia on clozapine and with obsessive–compulsive disorder: a comparison study. Comprehensive Psychiatry, 55: 130–6.CrossRefGoogle ScholarPubMed
Dykema, L (2018) Abrupt improvement in obsessive-compulsive symptoms upon discontinuation of clozapine. Journal of Clinical Psychopharmacology, 38: 88–9.CrossRefGoogle ScholarPubMed
Egerton, A, Brugger, S, Raffin, M, et al. (2012) Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology, 37: 2515–21.CrossRefGoogle ScholarPubMed
El-Shiekh, HE, Michail, VS, Al-Said, HM, et al. (2017) Obsessive–compulsive symptoms in schizophrenia. Middle East Current Psychiatry, 24: 174–80.CrossRefGoogle Scholar
El Dawla, AS, Assad, T, El Habiby, MM, et al. (2015) Obsessive–compulsive symptoms in Egyptian schizophrenic patients. Middle East Current Psychiatry, 22: 21–6.CrossRefGoogle Scholar
Englisch, S, Esslinger, C, Inta, D, et al. (2009) Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. Clinical Neuropharmacology, 32: 227–9.CrossRefGoogle ScholarPubMed
Eryılmaz, G, Sayar, GH, Ozten, E, et al. (2013) Aripiprazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia. Annals of General Psychiatry, 12(1): 40.CrossRefGoogle Scholar
Fenton, W, McGlashan, T (1986) The prognostic significance of obsessive-compulsive symptoms in schizophrenia. American Journal of Psychiatry, 143: 437–41.Google Scholar
Fonseka, TM, Richter, MA, Müller, DJ (2014) Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature. Current Psychiatry Reports, 16: 510.CrossRefGoogle ScholarPubMed
Fulford, D, Pearson, R, Stuart, BK, et al. (2014) Symptom assessment in early psychosis: the use of well-established rating scales in clinical high-risk and recent-onset populations. Psychiatry Research, 220: 1077–83.CrossRefGoogle ScholarPubMed
Galletly, C, Castle, D, Dark, F, et al. (2016) Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 50: 410–72.CrossRefGoogle ScholarPubMed
Glass, R (2009) Clinical Review: Lexapro (Escitalopram). US Food and Drug Administration (https://www.fda.gov/media/79164/download).Google Scholar
Glick, ID, Poyurovsky, M, Ivanova, O, et al. (2008) Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open label study of 15 patients. Journal of Clinical Psychiatry, 69: 1856–9.CrossRefGoogle ScholarPubMed
Gordon, A (1926) Obsessions in the relation to psychoses. American Journal of Psychiatry, 82: 647–59.CrossRefGoogle Scholar
Grover, S, Hazari, N, Chakrabarti, S, et al. (2015) Relationship of obsessive–compulsive symptoms/disorder with clozapine: a retrospective study from a multispeciality tertiary care centre. Asian Journal of Psychiatry, 15: 5661.CrossRefGoogle ScholarPubMed
Grover, S, Sahoo, S, Surendran, I (2018) Obsessive-compulsive symptoms in schizophrenia: a review. Acta Neuropsychiatrica, 31: 6373.CrossRefGoogle Scholar
Hagen, K, Hansen, B, Joa, I, et al. (2013) Prevalence and clinical characteristics of patients with obsessive-compulsive disorder in first-episode psychosis. BMC Psychiatry, 13: 156.CrossRefGoogle ScholarPubMed
Hagen, K, Solem, S, Hansen, B (2014) Cognitive behavioural therapy for obsessive-compulsive disorder with comorbid schizophrenia: a case report with repetitive measurements. Behavioural and Cognitive Psychotherapy, 42: 374–8.CrossRefGoogle ScholarPubMed
Hanisch, F, Friedemann, J, Piro, J, et al. (2009) Maintenance electroconvulsive therapy for comorbid pharmacotherapy-refractory obsessive-compulsive and schizoaffective disorder. European Journal of Medical Research, 14: 367–8.CrossRefGoogle ScholarPubMed
Hemrom, S, Pushpa, , Prasad, D, et al. (2009) Prevalence of obsessive–compulsive symptoms among patients with schizophrenia. Industrial Psychiatry Journal, 18: 7780.Google ScholarPubMed
Hoch, P, Polatin, P (1949) Pseudoneurotic forms of schizophrenia. Psychiatric Quarterly, 23: 248–76.CrossRefGoogle ScholarPubMed
Huber, G, Gross, G, Schuttler, R, et al. (1980) Longitudinal studies of schizophrenic patients. Schizophrenia Bulletin, 6: 592605.CrossRefGoogle ScholarPubMed
Huey, ED, Zahn, R, Krueger, F, et al. (2008) A psychological and neuroanatomical model of obsessive-compulsive disorder. Journal of Neuropsychiatry and Clinical Neuroscience, 20: 390408.CrossRefGoogle ScholarPubMed
Hwang, M, Buckley, PF (2018) Comorbidity and schizophrenia. Psychiatric Annals, 48: 544–5.CrossRefGoogle Scholar
Joint Formulary Committee (2019) British National Formulary 78: September 2019 – March 2020. Pharmaceutical Press.Google Scholar
Kim, SW, Shin, IS, Kim, JM, et al. (2008) Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. Journal of Clinical Psychopharmacology, 28: 349–52.CrossRefGoogle Scholar
Kim, JH, Ryu, S, Nam, HJ, et al. (2012) Symptom structure of antipsychotic-induced obsessive–compulsive symptoms in schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 39: 75–9.CrossRefGoogle ScholarPubMed
Krüger, S, Bräunig, P, Höffler, J, et al. (2000) Prevalence of obsessive-compulsive disorder in schizophrenia and significance of motor symptoms. Journal of Neuropsychiatry and the Neurosciences, 12: 1624.CrossRefGoogle ScholarPubMed
Laroche, DG, Gaillard, A (2016) Induced obsessive–compulsive symptoms (OCS) in schizophrenia patients under atypical antipsychotics (AAPs): review and hypotheses. Psychiatry Research, 246: 119–28.CrossRefGoogle Scholar
Lavin, MR, Halligan, P (1996) ECT for comorbid obsessive-compulsive disorder and schizophrenia. American Journal of Psychiatry, 153: 1652–3.Google Scholar
Leung, JG, Palmer, BA (2016) Psychosis or obsessions? Clozapine associated with worsening obsessive-compulsive symptoms. Case Reports in Psychiatry, 2016: 2180748.CrossRefGoogle ScholarPubMed
Mendes-Filho, VA, Belmonte-de-Abreu, P, Pedrini, M, et al. (2013) rTMS as an add-on treatment for resistant obsessive-compulsive symptoms in patients with schizophrenia: report of three cases. Revista Brasileira de Psiquiatria, 35: 210–1.Google ScholarPubMed
Mendes-Filho, VA, de Jesus, DR, Belmonte-de-Abreu, P, et al. (2016) Effects of repetitive transcranial magnetic stimulation over supplementary motor area in patients with schizophrenia with obsessive-compulsive-symptoms: a pilot study. Psychiatry Research, 242: 34–8.CrossRefGoogle ScholarPubMed
Mouchlianitis, E, Bloomfield, MAP, Law, V, et al. (2016) Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophrenia Bulletin, 42: 744–52.CrossRefGoogle ScholarPubMed
Mukhopadhaya, K, Krishnaiah, R, Taye, T, et al. (2009) Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern. Journal of Psychopharmacology, 23: 613.CrossRefGoogle ScholarPubMed
Nakao, T, Okada, K, Kanba, S (2014) Neurobiological model of obsessive–compulsive disorder: evidence from recent neuropsychological and neuroimaging findings. Psychiatry and Clinical Neurosciences, 68: 587605.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence (2009) Obsessive-Compulsive Disorder and Body Dysmorphic Disorder: Treatment (Clinical Guideline CG31). NICE.Google Scholar
National Institute for Health and Care Excellence (2014) Psychosis and Schizophrenia in Adults: Prevention and Management (Clinical Guideline CG178). NICE.Google Scholar
Owashi, T, Ota, A, Otsubo, T, et al. (2010) Obsessive-compulsive disorder and obsessive-compulsive symptoms in Japanese inpatients with chronic schizophrenia – a possible schizophrenic subtype. Psychiatry Research, 179: 241–6.CrossRefGoogle ScholarPubMed
Pauls, DL, Abramovitch, A, Rauch, SL, et al. (2014) Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nature Reviews: Neuroscience, 15: 410–24.CrossRefGoogle ScholarPubMed
Poyurovsky, M, Isakov, V, Hromnikov, S, et al. (1999) Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. International Clinical Psychopharmacology, 14: 95100.CrossRefGoogle ScholarPubMed
Poyurovsky, M, Faragian, S, Kleinman-Balush, V, et al. (2007) Awareness of illness and insight into obsessive-compulsive symptoms in schizophrenia patients with obsessive–compulsive disorder. Journal of Nervous and Mental Disease, 195: 765–8.CrossRefGoogle ScholarPubMed
Poyurovsky, M (2013) Schizo-Obsessive Disorder. Cambridge University Press.CrossRefGoogle Scholar
Rabe-Jablonska, J (2001) Obsessive–compulsive disorders in adolescents with diagnosed schizophrenia. Psychiatria Polska, 35: 4757.Google ScholarPubMed
Rajkumar, RP, Reddy, YC, Kandavel, T (2008) Clinical profile of “schizo-obsessive” disorder: a comparative study. Comprehensive Psychiatry, 49: 262–8.CrossRefGoogle ScholarPubMed
Rao, NP, Antony, A, Raveendranathan, D, et al. (2011) Successful use of maintenance electroconvulsive therapy in the treatment of clozapine-associated obsessive-compulsive symptoms in schizophrenia: a case report. Journal of ECT, 27: e37–8.CrossRefGoogle ScholarPubMed
Remington, G, Honer, W, Raedler, T (2017) Guidelines for the pharmacotherapy of schizophrenia in adults. Canadian Journal of Psychiatry, 62: 604–16.CrossRefGoogle ScholarPubMed
Reznik, I, Sirota, P (2000) Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. Journal of Clinical Psychopharmacology, 20: 410–6.CrossRefGoogle ScholarPubMed
Rodriguez, CI, Corcoran, C, Simpson, HB (2010) Diagnosis and treatment of a patient with both psychotic and obsessive-compulsive symptoms. American Journal of Psychiatry, 167: 754–61.CrossRefGoogle ScholarPubMed
Rosen, I (1956) The clinical significance of obsessions in schizophrenia. Journal of Mental Science, 103: 773–85.CrossRefGoogle Scholar
Sa, AR, Hounie, AG, Sampaio, AS, et al. (2009) Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Comprehensive Psychiatry, 50: 437–42.CrossRefGoogle ScholarPubMed
Sahoo, S, Grover, S, Nehru, R (2018) Comparison of neurocognitive domains in patients with schizophrenia with and without co-morbid obsessive–compulsive disorder. Schizophrenia Research, 201: 151–8.CrossRefGoogle ScholarPubMed
Schirmbeck, F, Esslinger, C, Rausch, F, et al. (2011) Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychological Medicine, 41: 2361–73.CrossRefGoogle Scholar
Schirmbeck, F, Zink, M (2013) Cognitive behavioural therapy for obsessive-compulsive symptoms in schizophrenia. Cognitive Behavioural Therapist, 6: 113.Google Scholar
Schirmbeck, F, Rausch, F, Englisch, S, et al. (2013) Differential effects of antipsychotic agents on obsessive–compulsive symptoms in schizophrenia: a longitudinal study. Journal of Psychopharmacology, 27: 349–57.CrossRefGoogle ScholarPubMed
Scotti-Muzzi, E, Saide, OL (2017) Schizo-obsessive spectrum disorders: an update. CNS Spectrums, 22: 258–72.CrossRefGoogle ScholarPubMed
Seedat, F, Roos, JL, Pretorius, HW, et al. (2007) Prevalence and clinical characteristics of obsessive-compulsive disorder and obsessive–compulsive symptoms in Afrikaner schizophrenia and schizoaffective disorder patients. African Journal of Psychiatry, 10: 219–24.Google ScholarPubMed
Shekelle, PG, Woolf, SH, Eccles, M, et al. (1999) Clinical guidelines: developing guidelines. BMJ, 318: 593–6.CrossRefGoogle ScholarPubMed
Stahl, SM (2013) Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (4th edn). Cambridge University Press.Google Scholar
Stryjer, R, Dambinsky, Y, Timinsky, I, et al. (2013) Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study. Internal Clinical Psychopharmacology, 28: 96–8.CrossRefGoogle Scholar
Sung-Wan, K, Bo-Ok, J, Jae-Min, K, et al. (2015) Associations of obsessive–compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness. Psychiatry Research, 226: 368–75.Google Scholar
Swets, M, Dekker, J, van Emmerik-van Oortmerssen, K, et al. (2014) The obsessive–compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates. Schizophrenia Research, 152: 458–68.CrossRefGoogle ScholarPubMed
Szmulewicz, AG, Smith, JM, Valerio, MP (2015) Suicidality in clozapine-treated patients with schizophrenia: role of obsessive-compulsive symptoms. Psychiatry Research, 230: 50–5.CrossRefGoogle ScholarPubMed
Tonna, M, Ottoni, R, Affaticati, A, et al. (2015) The impact of obsessive dimension on symptoms and functioning in schizophrenia. Psychiatry Research, 230: 581–4.CrossRefGoogle Scholar
Tundo, A, Salvati, L, Di Spigno, D, et al. (2012) Cognitive-behavioral therapy for obsessive-compulsive disorder as a comorbidity with schizophrenia or schizoaffective disorder. Psychotherapy and Psychosomatics, 81: 5860.CrossRefGoogle ScholarPubMed
Tundo, A, Salvati, L, Cieri, L, et al. (2015) Cognitive behavioral therapy for obsessive-compulsive disorder secondary to second-generation antipsychotics. Psychotherapy and Psychosomatics, 84: 188–9.CrossRefGoogle ScholarPubMed
Turkcan, A, Yanbay, H, Satmis, N, et al. (2007) Obsessive-compulsive symptoms in inpatients with schizophrenia: a preliminary study. Bulletin of Clinical Psychopharmacology, 17: 25.Google Scholar
van Os, J, Kapur, S (2009) Schizophrenia. Lancet, 374: 635–45.CrossRefGoogle ScholarPubMed
Villari, V, Frieri, T, Fagiolini, A (2011) Aripiprazole augmentation in clozapine-associated obsessive-compulsive symptoms. Journal of Clinical Psychopharmacology, 31: 375–6.CrossRefGoogle ScholarPubMed
Working Group on Schizophrenia (2004) Practice Guideline for the Treatment of Patients with Schizophrenia (2nd edn). American Psychiatric Association.Google Scholar
World Health Organization (2019) ICD-11 for Mortality and Morbidity Statistics (Version: 04/2019). (https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f1582741816). Accessed 20 Nov 2019.Google Scholar
Zhou, T, Baytunca, B, Yu, X, et al. (2016) Schizo-obsessive disorder: the epidemiology, diagnosis, and treatment of comorbid schizophrenia and OCD. Current Treatment Options in Psychiatry, 3: 235–45.CrossRefGoogle Scholar
Zink, M, Knopf, U, Kuwilsky, A (2007) Management of clozapine-induced obsessive–compulsive symptoms in a man with schizophrenia. Australian & New Zealand Journal of Psychiatry, 41: 293–4.CrossRefGoogle Scholar
Zink, M (2014) Comorbid obsessive-compulsive symptoms in schizophrenia: insight into pathomechanisms facilitates treatment. Advances in Medicine, 2014: 317980.CrossRefGoogle ScholarPubMed
Supplementary material: PDF

Udo et al. Supplementary Materials

Udo et al. Supplementary Materials 1

Download Udo et al. Supplementary Materials(PDF)
PDF 394 KB
Supplementary material: PDF

Udo et al. Supplementary Materials

Udo et al. Supplementary Materials 2

Download Udo et al. Supplementary Materials(PDF)
PDF 651 KB
Supplementary material: PDF

Udo et al. Supplementary Materials

Udo et al. Supplementary Materials 3

Download Udo et al. Supplementary Materials(PDF)
PDF 1 MB
Submit a response

eLetters

No eLetters have been published for this article.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Pharmacological management of comorbid obsessive–compulsive disorder and chronic non-affective psychosis
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Pharmacological management of comorbid obsessive–compulsive disorder and chronic non-affective psychosis
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Pharmacological management of comorbid obsessive–compulsive disorder and chronic non-affective psychosis
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *